Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 3/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CEL | P19835 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877973 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL15971435 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL10385540 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL25313409 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL5707624 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL25313563 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL3027416 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL446539 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1482399 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1867938 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12340996-B2 | Method for rapid on-site detection of fentanyl analogs using a miniature mass spectrometer | CHINESE ACADEMY OF INSPECTION AND QUARANTINE (CN) | 2025-06-24 | — | — | US | claimed |
| CN-117664949-A | Detection method of surface-enhanced Raman nano particles and fentanyl substances | 深圳海关工业品检测技术中心 | 2024-03-08 | — | — | CN | claimed |
| US-20230015987-A1 | METHOD FOR RAPID ON-SITE DETECTION OF FENTANYL ANALOGS USING A MINIATURE MASS SPECTROMETER | CHINESE ACADEMY OF INSPECTION AND QUARANTINE (CN) | 2023-01-19 | — | — | US | claimed |
| CN-114171692-A | Organic electroluminescent device and display device | 昆山国显光电有限公司 | 2022-03-11 | — | — | CN | claimed |
| EP-1654225-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2007-11-28 | — | — | EP | claimed |
| EP-1654225-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | Amgen, Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050256161-A1 | Melanin concentrating hormone receptor antagonists | AMGEN INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005019240-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-0259752-A2 | Saccharide phosphates, their esters and method for their preparation | BAYER AG (DE) | 1988-03-16 | — | — | EP | claimed |
| US-12523665-B2 | In-field colour test for screening fentanyl and analogues thereof | UNIVERSITY OF TECHNOLOGY SYDNEY (AU) | 2026-01-13 | — | — | US | disclosed |
| US-12340996-B2 | Method for rapid on-site detection of fentanyl analogs using a miniature mass spectrometer | CHINESE ACADEMY OF INSPECTION AND QUARANTINE (CN) | 2025-06-24 | — | — | US | disclosed |
| CN-118556058-A | New method | 细胞内治疗公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240239922-A1 | PHOTOCURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| EP-0144894-A2 | Therapeutic application of substituted O-acyl-glycosides | BAYER AG (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0143385-A2 | Phosphorylised glycosil amides, ureas, carbamates and thiocarbamates, method for their preparation and their use | BAYER AG (DE) | 1985-06-05 | — | — | EP | disclosed |
| US-4389345-A | 3-Oxoestra-17-acetonitrile and unsaturated analogs | G.D. SEARLE & CO. (US) | 1983-06-21 | — | — | US | disclosed |
| EP-0077040-A1 | 3-Oxaestra-17-acetonitrile and unsaturated analogs, a process for their preparation and pharmaceutical compositions containing said compounds | G.D. Searle & Co. (US) | 1983-04-20 | — | — | EP | disclosed |
| US-4198429-A | BRONCHOSPASMOLYTIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
| US-3971825-A | (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS | SANKYO COMPANY LIMITED (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256161-A1 | Melanin concentrating hormone receptor antagonists | MCHR1, MC1R, NPY1R | SIGMAR1 165/4885CYP1A2 394/4885EPHX1 1726/4885 |
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | PPOX, ERCC1, ERCC5 | SIGMAR1 4678/4885CYP1A2 3273/4885EPHX1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.